Ongoing trials incorporating novel agents in the frontline setting for advanced-stage HL
| Trial . | Trial phase . | Patient population . | Treatment regimen . |
|---|---|---|---|
| NCT03033914 | Phase 1 | Stage III-IV HL with IPS ≥ 3 or positive interim PET | A(B)VD followed by nivolumab |
| NCT03226249 | Phase 2 | Early- and advanced-stage HL | Pembrolizumab followed by AVD |
| NCT02758717 | Phase 2 | Age ≥60 or inability to tolerate chemotherapy due to impaired cardiac, pulmonary, or renal function | Brentuximab and nivolumab |
| NCT03331731 | Phase 2 | Age ≥65 or inability to tolerate chemotherapy due to impaired cardiac, pulmonary, or renal function | Pembrolizumab |
| Trial . | Trial phase . | Patient population . | Treatment regimen . |
|---|---|---|---|
| NCT03033914 | Phase 1 | Stage III-IV HL with IPS ≥ 3 or positive interim PET | A(B)VD followed by nivolumab |
| NCT03226249 | Phase 2 | Early- and advanced-stage HL | Pembrolizumab followed by AVD |
| NCT02758717 | Phase 2 | Age ≥60 or inability to tolerate chemotherapy due to impaired cardiac, pulmonary, or renal function | Brentuximab and nivolumab |
| NCT03331731 | Phase 2 | Age ≥65 or inability to tolerate chemotherapy due to impaired cardiac, pulmonary, or renal function | Pembrolizumab |